PROVIDER PROFILE · NPI 1801976733

Melanie CostaM.D.

DermatologyPittsburgh, PAI

MEDICARE UTILIZATION · PART B · 2024

Total beneficiaries

1,139

Unique beneficiaries

—

Total services

1,554

Distinct HCPCS

Medicare payment

$58K

Peer benchmark

Total Medicare services vs. 531 Dermatology providers in PA — below median (cohort median 2,070).

PRESCRIBING · PART D · 2024

Total Rx claims

1,463

Beneficiaries

—

Total drug cost

$110K

Distinct drugs

Brand share

25.4%

Top prescribed drugs

Betamethasone/Propylene Glyc305 claims

Triamcinolone Acetonide256 claims

Doxycycline Hyclate193 claims

Ketoconazole118 claims

Clobetasol Propionate113 claims

QUALITY · MIPS · 2024

Final MIPS score

97.5

Quality

24.6

Cost

77.0

Improvement activities

40.0

Promoting interop.

97.0

Payment adjustment

0.94%

Group

INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024

Total received

$271

Payment records

By payment type

Food and Beverage$271

REFERRAL NETWORK

Where Melanie Costa's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 7 inbound referrers · 0 outbound destinations.

Receives referrals from

Inbound — who sends patients here

Physician	Patients	Visits
Rabkin Dermatopathology Laboratory, P.C. Clinical Laboratory · Pittsburgh, PA	51	59
UPMC PASSAVANT	42	66
WEST PENN ALLEGHENY HEALTH SYSTEM INC	24	39
HOUSE, NANCY	21	22
WALLACE, MICHAEL	15	20
ALLEGHENY & CHESAPEAKE PHYSICAL THERAPISTS INC	13	16
WEST PENN ALLEGHENY HEALTH SYSTEM INC.	11	15

Refers patients to

Outbound — where patients go next

No outbound pairs above the suppression threshold.

Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.

CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore

OIG/SAM exclusion screening, sanctions history